Xilio Therapeutics XLO
NASDAQ XLO
$8.03 -0.37 (-4.40%)
At close: Oct 22, 2026 · 4:00 PM EDT

Xilio Therapeutics (XLO) Depreciation & Amortization (CF) (2020 - 2026)

Updated

Xilio Therapeutics (XLO) posted Depreciation & Amortization (CF) of $331,000 for Q2 2026, down 13.1% from $381,000 a year earlier and down 3.8% from the prior quarter.

Analysis

Xilio Therapeutics (XLO) Depreciation & Amortization (CF) (2020 - 2026) Analysis & Trends

For the trailing twelve months through Jun 30, 2026, Depreciation & Amortization (CF) at Xilio Therapeutics was $1.34 million, down 18.1% year-over-year; for FY2025, it came in at $1.54 million, down 6.3% from FY2024.

  • Annual Depreciation & Amortization (CF) shows a five-year compound annual growth rate of 7.7% (FY2020 to FY2025).
  • In prior years, Xilio Therapeutics' Depreciation & Amortization (CF) was $1.64 million in FY2024 (-13.5%), $1.9 million in FY2023 (+2.9%), $1.85 million in FY2022 (+23.2%) and $1.5 million in FY2021 (+40.8%).
  • Quarterly Depreciation & Amortization (CF) has run from a low of $323,000 in Q4 2025 to a high of $499,000 in Q1 2023 over five years.
  • On a year-over-year basis, Depreciation & Amortization (CF) has declined in each of the last five quarters, with an average decline of 13.0% over the last eight quarters.
  • The strongest year-over-year quarter for Depreciation & Amortization (CF) in the past five years was Q1 2022, with growth of 25.7%; the weakest was Q1 2026, with a decline of 30.8%.
  • According to Business Quant data, Depreciation & Amortization (CF) for the three prior quarters was $344,000 (Q1 2026), $323,000 (Q4 2025) and $340,000 (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Dep. & Amort. (Qtr)
1 Eli Lilly 1,165.22 Bn 1,133.81 Bn 19.71 Bn 534.00 Mn
2 Johnson & Johnson 646.28 Bn 566.14 Bn 17.30 Bn 2.12 Bn
3 AbbVie 503.17 Bn 476.28 Bn 12.70 Bn 194.00 Mn
4 Merck 365.23 Bn 319.60 Bn 12.21 Bn 599.00 Mn
5 Novartis Ag 302.66 Bn 266.65 Bn 11.24 Bn -
6 Astrazeneca 267.39 Bn 241.08 Bn 12.86 Bn 1.93 Bn
7 Amgen 241.61 Bn 197.01 Bn 7.24 Bn 1.11 Bn
8 Gilead Sciences 194.67 Bn 168.86 Bn 6.22 Bn 98.00 Mn
9 Pfizer 172.91 Bn 119.55 Bn 10.94 Bn 1.62 Bn
10 Xilio Therapeutics 157.76 Mn -369.91 Mn - 331,000.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 331,000.00
Mar 31, 2026 344,000.00
Dec 31, 2025 323,000.00
Sep 30, 2025 340,000.00
Jun 30, 2025 381,000.00
Mar 31, 2025 497,000.00
Dec 31, 2024 376,000.00
Sep 30, 2024 380,000.00
Jun 30, 2024 445,000.00
Mar 31, 2024 443,000.00
Dec 31, 2023 449,000.00
Sep 30, 2023 460,000.00
Jun 30, 2023 492,000.00
Mar 31, 2023 499,000.00
Dec 31, 2022 489,000.00
Sep 30, 2022 473,000.00
Jun 30, 2022 445,000.00
Mar 31, 2022 440,000.00
Dec 31, 2021 394,000.00
Sep 30, 2021 382,000.00
API Access

Xilio Therapeutics Depreciation & Amortization (CF) API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=depreciation-and-amortization-cf&ticker=XLO&period=max&api_key=YOUR_API_KEY